Document is current
Any future updates will be listed below
-
Authors
Dileo, Rachel https://orcid.org/0009-0002-6921-8086
Mewawalla, Prerna
Babu, Kalaivani
Yin, Yue
Strouse, Christopher
Chen, Ethan https://orcid.org/0009-0009-8434-2369
Shaikh, Hira
Davis, James A. https://orcid.org/0000-0001-7978-1652
Green, Kimberly M.
Alkharabsheh, Omar
Rashid, Aliya
Pokhrel, Bidushi
Ahmed, Nausheen https://orcid.org/0000-0003-4336-4982
Abdallah, Al-Ola
Hashmi, Hamza https://orcid.org/0000-0002-4129-5867
- License Information
-
More Information
Article History
Received: 8 October 2024
Revised: 4 January 2025
Accepted: 3 February 2025
First Online: 10 March 2025
Conflict of interest
: Authors RD, KB, YY, EC, HS, KG, OA, AR, BP, and A-OA have no conflicts of interest to disclose. HH disclosed Janssen, Amgen, Honoraria, and Karyopharm as conflicts of interest. PM disclosed Celegene and Pfizer as conflict of interests. CS has disclosed Pfizer, Janssen, Bristol Meyer Squibb, Seagen, and Poseida as conflict of interests. JD has disclosed Janssen Biotech as a conflict of interest. NA has disclosed BMS, Kite/Gilead, and Legend Biotech as conflicts of interest.
: All methods were performed in accordance with the relevant guidelines and regulations. As this is a multicenter consortium study, the study was reviewed and approved by the institutional review boards (incorporating the ethics committee) at each site. As this is a multicenter consortium study utilizing retrospective data, the study was reviewed and approved by the institutional review boards (incorporating ethics committee) at each site, and the need for obtaining informed consent from the participants was waived.
: This multicenter study was a collaborative effort by US Myeloma Innovations Research Collaborative (USMIRC) and was approved by respective institutions’ Institutional Review Board.
